A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 5, 2000, Pages 1105-1108

  Bourhis, J ^a   De Crevoisier, R ^a   Abdulkarim, B ^a   Deutsch, E ^b   Lusinchi, A ^a   Luboinski, B ^a   Wibault, P ^a   Eschwege, F ^a  

^a Radiation Oncology   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Accelerated radiotherapy; Amifostine; Mucositis; Radioprotector

Indexed keywords

AMIFOSTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ERYTHEMA; FEEDING APPARATUS; HEAD AND NECK CARCINOMA; HUMAN; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TECHNIQUE; VOMITING;

ADULT; AGED; AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEASIBILITY STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; STOMATITIS;

EID: 0034653941     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00532-5     Document Type: Article

References (23)

1. Grdina D., Sigdestad C. Radiation protectors The unexpected benefit . Drug Metab Rev. 20:1989;13-42.
2. Kataoka Y, Basic I, Perrin; et al. Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neutrons and 60co gamma rays in mice. Int J Radiat Biol 1992;61:387-392.
3. Milas L., Hunter N., Hisao I., Peters L. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721. Int J Radiat Oncol Biol Phys. 10:1984;41-48.
4. Rojas A., Stewart F., Soranson J., Smith K., Denekamp J. Fractionation studies with WR-2721 Normal tissue and tumor . Radiother Oncol. 6:1986;51-60.
5. Utley J., Phillips T., Kane L. Protection of normal tissue by WR-2721 during fractionated irradiation. Int J Radiat Oncol Biol Phys. 1:1976;699-703.
6. Wasserman T., Phillips T., Ross G. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol. 21:1994;21-25.
7. Yuhas J., Spellman J., Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials. 3:1980;211-216.
8. Zhang X., Lai P., Taylor Y. Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR-1065. Int J Radiat Onol Biol Phys. 24:1992;713-719.
9. El Ghissassi M., Verheagh G., Hainaut P. Modulation of wtp53 activity by the aminothiol amifostine. Proc Am Soc Clin Oncol. 16:1997;1958.
10. Aguillera J., Newton G., Fahey R. Thiol uptake by chinese hamster V79 cells and aerobic radioprotection as a function of the net charge on the thiol. Radiat Res. 130:1992;194-204.
11. Smoluk G., Fahey R., Calabro-Jones P.M., et al. Radioprotection of cells in culture by WR-2721 and derivatives Form of the drug responsible for protection . Cancer Res. 48:1988;3641-3647.
12. Brizel D., Sauer R., Wannenmacher M., Henke M., Eschwege F., Wasserman T. Randomized phase III trial of radiation +/- amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol. 17:1998;1487.
13. Bourhis J., Wibault P., Lusinchi A., Bobin S., Eschwege F. Status of accelerated fractionated radiotherapy in head and neck squamous cell carcinoma. Current Opin Oncol. 9:1997;262-266.
14. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trail of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 44:1997;123-136.
15. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation compared to conventional fractionation improves locoregional control in the radiotherapy of advanced head and neck cancer Results of the EORTC 22851 randomized trial . Radiother Oncol. 44:1997;39-46.
16. Overgaard J., Sand Hansen H., Overgaard M., et al. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck A randomized multicenter study of 5 versus 6 fractions per week. Report from the DAHANCA 7 trial . Int J Radiat Oncol Biol Phys. 39:1997;188.
17. Bourhis J., Fortin A., Dupuis O., Janot F., Marandas P., Schwaab G., Wibault P., Luboinski B., Eschwege F. Very accelerated radiotherapy Preliminary results in locally unresectable head and neck squamous cell carcinoma . Int J Radiat Oncol Biol Phys. 32:1995;747-752.
18. Kaanders J., Pop L., Marres H., et al. Accelerated radiotherapy with carbogen and nicotanamide (ARCON) for laryngeal cancer. Radiother Oncol. 48:1998;115-122.
19. Bourhis J., Wibault P., Eschwege F. Very accelerated fractionation. Int J Radiat Oncol Biol Phys. 32:1996;889-890.
20. Kligerman M., Turrisi A., Urtasun R., et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys. 14:1988;1119-1122.
21. McDonald S., Meyerowitz C., Smudzin T., Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys. 29:1994;747-754.
22. Landauer M., Davis H., Dominitz J. Long term effect of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. Toxicology. 49:1988;315-323.
23. Buntzel J., et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 9:1998;505-509.